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PML—RAR (retinoic acid receptor)a is the hallmark protein of acute promyelocytic leukaemia, a highly malignant subtype of acute
myeloid leukaemia that accounts for approximately 10% of all AML cases. Recently, several studies have been set out to obtain a
comprehensive genome-wide view of the molecular actions of this chimeric protein. In this review, we highlight the new insights that
arose from these studies, in particular focussing on newly identified PML–RARa target genes, its interplay with RXR and deregulation
of epigenetic modifications.
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Acute promyelocytic leukaemia (APL) is a distinctive subtype of
acute myeloid leukaemia (AML) that accounts for approximately
10% of all AML cases (Jing, 2004). The disease represents a highly
malignant form of leukaemia with high bleeding tendency and a
fatal course of only few weeks (Wang and Chen, 2008). The main
diagnostic feature of APL is an aberrant chromosomal transloca-
tion that juxtaposes the PML gene on chromosome 15 and the
retinoic acid receptor (RAR)a gene on chromosome 17 (Kakizuka
et al, 1991). The resultant chimeric protein, which is found in over
95% of human APLs (Di Croce, 2005), retains the DNA-binding
and ligand-binding domains of RARa and the multimerisation
domain of PML. In normal cells PML is a main constituent of
nuclear bodies, which are matrix-associated multiprotein-contain-
ing domains involved in various biological functions like
DNA-damage response and microorganism resistance through
regulation of a wide range of proteins, among which are various
transcription factors (Lallemand-Breitenbach and de The, 2010). In
contrast, in APL, the expression of PML–RARa disrupts the
localisation of the wild-type PML from nuclear bodies to numerous
micro speckles (Brown et al, 2009) and induces a maturation block
at the promyelocytic level (Wang and Chen, 2008). All-trans
retinoic acid (ATRA) and arsenic trioxide (ATO) are the two most
important drugs in clinical use for the treatment of early-
diagnosed APL. Both ATRA and ATO degrade the PML–RARa
fusion protein by acting on the RARa and PML moieties,
respectively. ATRA mainly degrades the protein through proteosome-
mediated pathways (Zhu et al, 1999) and caspases (Nervi et al,
1998), while ATO-induced degradation is initiated through
sumoylation of the PML moiety. Both treatments ultimately lead
to restoration of PML nuclear bodies (Lallemand-Breitenbach et al,
2008; Zhang et al, 2010), but whether this is important for curing
the disease is an open question.
Various mechanisms have been proposed for PML–RARa
functioning. It has been suggested that PML–RARa can form
homodimers without RXR (Minucci et al, 2000) or that it forms
PML–RARa oligomers that heterodimerise with RXR (Perez et al,
1993; Jansen et al, 1995). In addition, it has been suggested that
during transformation PML–RARa induces a multitude of
alterations in the chromatin architecture. These alterations are
achieved through the recruitment of various epigenetic-modifying
factors, like histone deacetylase complexes such as SMRT (Lin
et al, 1998) and N-CoR (Grignani et al, 1998), and DNA
methyltransferases (Di Croce et al, 2002). In addition, recent
evidence suggests co-recruitment of the histone methyltransferases
SUV39H1 and polycomb repressor complexes, which dictate the
epigenetic state of H3K9 (Carbone et al, 2006) and H3K27 (Villa
et al, 2007), respectively. Unfortunately, most of these studies
showed epigenetic alterations only around a limited set of binding
regions, in most cases the RARb promoter. This was largely due to
unavailability of the genome-wide PML–RARa target site reper-
toire. However, the recent advances in high-throughput tools have,
for the first time, made it possible to look at the genome-wide
actions of PML–RARa and different epigenetic marks associated
with its binding. Indeed, two recent studies have provided a more
global picture of PML–RARa functioning by identifying binding
regions of PML–RARa, using state-of-the-art ChIP-seq and ChIP-
on-chip technologies. Importantly, the new technologies even
allowed extension from the commonly used model cell lines to
primary APL blasts, highlighting the new opportunities that have
now become available.
In this review we will focus on the various aspects of PML–
RARa functioning with respect to its genome-wide binding
spectrum, its interplay with RXR and its regulation of various
epigenetic modifications. In addition, we will discuss some of the
newly identified target genes and target pathways of PML–RARa.
ALTERED RAR SIGNALLING IN APL CELLS
All-trans retinoic acid belongs to the group of vitamin A-derived
substances and binds three major RARs, RARa, b and g. The full
execution of the ATRA signalling pathway operates by inducibly
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with spacing 2 or 5 (DR2 or DR5) in their promoter (de The et al,
1991). Retinoid signalling has a key role in various developmental
and differentiation processes. According to the classical model,
RAR and RXR, another nuclear receptor, heterodimerise under
non-ATRA conditions, recruit co-repressors and silence target
gene expression. In this model, RAR binding to ATRA results in a
conformational change in the RXR–RAR heterodimer, allowing
recruitment of gene-activating complexes and resultant gene
expression. In APL, PML–RARa is thought to behave functionally
as an altered RARa that has lost the potential to respond to
fluctuations in physiological ATRA concentration, and as a result
acts as a constitutive transcriptional repressor for DR2- or DR5-
containing genes. Strikingly, recent studies that analysed the
genome-wide PML–RARa binding sites not only identified DR2
and DR5 elements as the primary PML–RARa response elements,
but also regions containing DR1, DR3 and DR4 motifs and even
more atypical DR motifs with various spacing and orientation were
detected (Martens et al, 2010), thereby extending in vivo previous
in vitro data (Kamashev et al, 2004). This rather diverse repertoire
of response elements present at the PML–RARa binding sites
underscores the idea of a gain of DNA-binding capacity as
an essential feature of PML–RARa-mediated transformation. In
addition to this extended binding potential, global binding data of
PML–RARa using ChIP-seq revealed PML–RARa binding to the
RARa, RARb and RARg genes itself (Table 1), suggesting that
expression of these proteins is directly regulated by PML–RARa
(Martens et al, 2010). All these data suggest that PML–RARa
affects ATRA signalling at multiple levels: first by regulating
expression of the genes involved in transmitting the ATRA signals,
second through an altered regulation of classical DR2-and DR5-
containing RAR/RXR target genes and third through an extension
of the (PML-)RAR binding potential towards more degenerate
DR-containing regulatory sites.
PML–RARa HETERODIMERISES WITH RXR
Although oligomerisation of the RARa fusion proteins has been
considered to be a crucial requirement to their oncogenic potential
(Minucci et al, 2000), several studies support a role of RXR in the
PML–RARa transformation process. RXR was already described as
part of the PML–RARa oncogenic complex in in vitro settings
(Kamashev et al, 2004). In addition, recent studies highlighted the
importance of RXR in PML–RARa-mediated transcriptional repres-
sion (Zeisig et al, 2007; Zhu et al, 2007). These studies showed that
impaired RXR binding by PML–RARa mutants impairs APL
development in transgenic mice while still retaining the transform-
ing potential in vitro. Furthermore, they showed that silencing of
RXR by shRNA suppresses the RARa fusion-mediated transforma-
tion in vitro. These studies were corroborated and extended by the
identification of genome-wide association of RXR with PML–RARa
(Martens et al, 2010). For 99% of PML–RARa binding sites,
association of RXR was detected. Together, these studies highlight
the importance of RXR in the PML–RARa-mediated transformation
process. It may therefore be interesting to also test RXR antagonists
(Altucci et al, 2007) in this subtype of AML.
PML–RARa CROSS TALKS WITH OTHER
TRANSCRIPTION FACTORS
Apart from interacting with RXR, PML–RARa has been suggested
to interact with many other proteins. Amongst these are various
key haematopoietic regulatory transcription factors such as GATA-2,
PU.1 and AP-1 factors. PML–RARa is proposed to be involved in
inhibition of AP-1 transcriptional activity in an ATRA-dependent
manner. This is illustrated by the observation that PML–RARa
interacts with c-Jun and c-Fos and that the repressive effect on AP1
target sites is reversed by ATRA treatment (Doucas et al, 1993).
There is also evidence of a physical association of GATA2 with
PML–RARa. This interaction is suggested to result in enhanced
GATA-2-dependent transactivation capacity (Tsuzuki et al, 2000).
In line with these two studies is the observation that PML–RARa
binding was detected not only near several AP1 factors, such as
JUNB and JUND, but also near GATA2 (Table 1) (Martens et al,
2010), suggesting that these factors are affected both at the level of
their expression and in their targeting capacities. In addition, we
observed PML–RARa binding at several other key regulators of
haematopoiesis such as PU.1 (see below) RUNX1, RUNX3 and
GFI1 (Table 1). This extends the observation that PML–RARa
regulates the classical targets of the retinoic acid signalling
pathway to many other key players in haematopoiesis.
BINDING OF PML–RARa WITH PU.1
PU.1 is a protein that is essential for the haematopoietic
differentiation process. PU.1 mutants lead to embryonic lethality
at a late gestational stage (Scott et al, 1994). Mice that have
homozygous disruption of the DNA-binding domain of PU.1 have
severe septicaemia and die within 48h of their birth (McKercher
et al, 1996). In addition, PU.1 has been shown to be essential for
reprogramming B-cells into the myeloid lineage (Xie et al, 2004).
Already in 2006 it was proposed that PML–RARa interacts with
PU.1 and that the action of PU.1 is suppressed upon expression of
PML–RARa, thereby resulting in a differentiation block (Mueller
et al, 2006). In these studies, ATRA treatment and the ensuing
PML–RARa degradation resulted in restoration of PU.1 expres-
sion and a release of the differentiation block. These studies
already hinted at the molecular interplay of PU.1 with
PML–RARa. A recent study based on genome-wide binding of
PML–RARa using ChIP-sequencing in a PML–RARa inducible cell
model further shed light on the PU.1 and PML–RARa interaction
(Wang et al, 2010). In this study, more than 84% of the detected
PU.1 motifs were found in the close vicinity of variably spaced direct
repeats (DRs). Further functional analysis suggested that the
binding of PML–RARa to the regions containing both PU.1 and
DRs is a prerequisite for subsequent repression of chromatin at
Table 1 Binding targets of PML–RARa (HG18)
Gene
name Chromosome
Start
PML–RARa
peak
End
PML–RARa
peak Peak location
GFI1 chr1 92714254 92714749 Gene body
RUNX1 chr21 35159419 35160205 Gene body
RUNX3 chr1 25221279 25222212 Distant
JUND chr19 18263175 18264260 Upstream far
JUNB chr19 12760448 12760879 Upstream near
GATA2 chr3 129725052 129725491 Distant
SETDB1 chr1 149165218 149165613 Upstream near
DNMT3A chr2 25377769 25378201 Gene body
JMJD1A chr2 86521292 86521853 Upstream near
HDAC4 chr2 239913436 239913935 Gene body
HDAC9 chr7 18323574 18323895 Distant
PRMT3 chr11 20365226 20365660 Upstream near
SETD8 chr12 122434062 122434727 Gene body
PRMT7 chr16 66947562 66948286 Gene body
JMJD3 chr17 7682360 7683526 Upstream near
DOT1L chr19 2119325 2119752 Gene body
PU.1 (SPI1) chr11 47337456 47338471 Gene body
RARA chr17 35762690 35763210 Gene body
RARB chr3 25444370 25444950 Upstream near
RARG chr12 51897334 51897732 Gene body
Abbreviation: RAR, retinoic acid receptor.
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gene was found to be a direct target of PML–RARa (Martens et al,
2010). Interestingly, binding of PML–RARa was not detected at
the promoter regions but rather in the third intron of the PU.1
gene (Table 1). As this intronic region has also been reported to
contain the transcription start site of an antisense transcript that
acts as a putative negative regulator of PU.1 expression (Ebralidze
et al, 2008), these results identify for the first time PML–RARa-
mediated regulation of a non-coding transcript.
PML–RARa AFFECTS THE EPIGENOME
Multiple studies have suggested that central to oncogenic
transformation in APLs is the PML–RARa-induced mis-targeting
of the epigenetic machinery, thereby causing a perturbation of the
normal epigenetic landscape. Genome-wide binding analysis of
PML–RARa (Martens et al, 2010) revealed that various enzymes
that can set different chromatin modifications are targeted by
PML–RARa, including JMJD3 (H3K27me3 demethylation),
SETDB1, JMJD1A (H3K9 modifiers), deacetylases like HDAC4
and 9, and genes involved in DNA methylation, such as DNMT3A
(Table 1). These findings suggested that PML–RARa expression
has the potential to confer a genome-wide alteration in epigenetic
make-up. In addition to the direct transcriptional regulation of
epigenetic enzymes, different labs have explored the epigenetic
marks that are recruited by PML–RARa itself. Histone marks such
as H3K27me3 and H3K9me3, as well as DNA methylation, have
been proposed to be positively correlated with PML–RARa
binding, whereas H3 acetylation was associated with loss of
PML–RAR binding. The dynamic changes of DNA methylation,
H3K9me3 and H3K27me3 functioning are suggested to be
regulated by DNA methyltransferases, histone methyltransferase
(SUV39H1) and polycomb repressive complex 2 (PRC2), respec-
tively, and all these proteins have been suggested to interact with
the PML–RARa complex in several independent studies (Di Croce
et al, 2002; Carbone et al, 2006; Villa et al, 2007). H3 acetylation
was the first chromatin modification associated with PML–RARa
binding and is a mark that is negatively correlated with
PML–RARa binding. Mechanistically, this is thought to be achieved
through PML–RARa-mediated recruitment of HDACs (Grignani
et al, 1998; Lin et al, 1998). Indeed, in vivo studies could show that
there is a significant increase of H3 acetylation upon ATRA-
mediated degradation of PML–RARa at the RARb promoter (Villa
et al, 2007). Still, the limiting factor to this observation and also
other studies that investigated epigenetic marks was the number of
PML–RARa binding regions addressed and, therefore, the general-
ity of the proposed mechanisms. The recent genome-wide interro-
gation of APL (Martens et al, 2010) allowed for the first time
expansion to all binding regions of PML–RARa.T h i ss h o w e dt h a t
there was a significant regulation of local H3 acetylation at more
than 80% of the PML–RARa binding regions, illustrated by the
observation that H3 acetylation levels at these sites were signifi-
cantly elevated upon ATRA-induced PML–RARa degradation. In
contrast, changes in other epigenetic marks such as H3K9me3,
H3K27me3 and DNA methylation could not be generalised towards
all PML–RARa binding sites, as the vast majority of sites did not
show a significant change after ATRA treatment. These findings are
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Figure 1 Model of PML–RARa binding. (A) PML–RARa in conjunction with RXR and PU.1 binds DR motifs and recruits repressor complexes, resulting
in histone hypoacetylation and transcriptional silencing. (B) All-trans retinoic acid (ATRA) or arsenic trioxide (ATO) mediates degradation of PML–RARa,
which is replaced by the RARa/RXR heterodimer, resulting in recruitment of activating complexes and transcriptional activation. HAT, histone
acetyltransferase; HDAC, histone deacetylase.
Genome-wide functions of PML–RARa
S Saeed et al
556
British Journal of Cancer (2011) 104(4), 554–558 & 2011 Cancer Research UKof significant worth, as they point out the importance of the role of
histone deacetylases in maintenance of repressed chromatin
architecture at PML–RARa binding sites. This sanctions the idea
of making HDACs direct targets for therapeutic treatment of APL by
using specific inhibitors for these proteins.
OUTLOOK
In this review, we focused on two recent studies that describe a
global analysis of PML–RARa (Martens et al,2 0 1 0 ;W a n get al,
2010). Both studies have shown nearly 3000 genome-wide direct
targets of PML–RARa by using high-throughput sequencing and
array-based technologies, and provided a significant step forward in
understanding PML–RARa-mediated leukaemogenesis. Although
these studies used independent platforms, several common conclu-
sions were drawn (Figure 1). One of these is the extended binding
repertoire of PML–RARa in comparison with the non-fused RAR.
Indeed, direct, inverted and everted repeats with various spacing and
orientation were detected in vivo for PML–RARa binding sites in
comparison with the classical DR2 and DR5 motifs that are the
hallmarks of heterodimerised RARa/RXR binding regions. In
addition to the DR motifs, the discovery of DNA motifs for PU.1
resulted in the finding that PU.1 colocalises with PML–RAR.
The above studies highlighted the fact that PML–RARa not only
binds to the promoter regions of target genes but also has a rather
diverse repertoire of binding sites. This complex binding spectrum
suggests a potential influence on long-range chromosomal interac-
tions by PML–RARa. The wide-ranging molecular alterations
induced by PML–RARa are further illustrated by the fact that
PML–RARa regulates several key regulators of normal haemato-
poiesis, such as PU.1, GATA-2, RUNX1 and many others, as well as
different pathways such as RAR signalling. In addition, exploration
of the epigenetic environment of the APL genome before and after
ATRA treatment gave significant insights into PML–RARa
chromatin regulation. An inverse correlation of PML–RARa with
H3 acetylation was revealed at the PML–RARa binding sites
themselves, while the genome-wide epigenetic environment was also
significantly remodelled. Still, more in-depth functional studies are
needed to provide an answer as to whether histone H3 acetylation
levels or other epigenetic markings are crucial in the PML–RARa-
induced transformation process. Nevertheless, current data already
hint at potential drug targets such as acetyltransferases and
deacetylases, as well as RXR for treatment of APL.
Despite the wealth of important insights on PML–RARa
functioning provided by the above studies, the question still remains
as to what the crucial determinant for PML–RARa binding to a
particular region actually is. Is it the underlying motif, interaction
with other transcription factors, the chromatin accessibility, or a
combination of all three? In order to obtain a better comprehension
of normal haematopoiesis and leukaemia, it will be important to
address these crucial questions. At the same time, deeper insight is
required into the molecular behaviour of other oncofusion proteins
that harbour functional properties similar to PML–RARa’s such as
AML1-ETO, which is the result of the t(8;21) chromosomal
translocation, or the inv (16) translocation that gives rise to the
CBFb-MYH11 oncofusion protein (Martens and Stunnenberg, 2010).
A comparative analysis of the molecular actions of several oncofusion
proteins is expected to uncover some of the more general
mechanisms that are used by these proteins to transform cells.
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